Literature DB >> 2622620

North Carolina macular dystrophy, revisited.

K W Small1.   

Abstract

Progression of the maculopathy in North Carolina macular dystrophy (NCMD) was not well documented. Thus, the author recently examined 22 affected members of the original kindred. Evidence of progression of the macular disease was sought through comparison of the recent fundus findings with old fundus photographs and from subjective complaints of worsening visual acuity. Only 1 of the 22 affected subjects had evidence of such change. Additionally, two new findings of NCMD were observed: (1) severe macular lesions which were staphylomatous or excavated in appearance, not flat, and atrophic as previously described; and (2) peripheral retinal drusen variably present in affected subjects, in contrast to the "normal peripheral retina" originally described. These new findings, along with the generally stable course of the disease would seem to alter our understanding of the relationship of NCMD to other dominant macular dystrophies.

Entities:  

Mesh:

Year:  1989        PMID: 2622620     DOI: 10.1016/s0161-6420(89)32655-8

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  11 in total

Review 1.  Genotype-phenotype correlations and differential diagnosis in autosomal dominant macular disease.

Authors:  A Iannaccone
Journal:  Doc Ophthalmol       Date:  2001-05       Impact factor: 2.379

2.  North Carolina macular dystrophy: clinical features, genealogy, and genetic linkage analysis.

Authors:  K W Small
Journal:  Trans Am Ophthalmol Soc       Date:  1998

3.  An ancestral core haplotype defines the critical region harbouring the North Carolina macular dystrophy gene (MCDR1).

Authors:  C G Sauer; H D Schworm; M Ulbig; A Blankenagel; K Rohrschneider; D Pauleikhoff; T Grimm; B H Weber
Journal:  J Med Genet       Date:  1997-12       Impact factor: 6.318

4.  North Carolina's dominant progressive foveal dystrophy: how progressive is it?

Authors:  K W Small; J Killian; W C McLean
Journal:  Br J Ophthalmol       Date:  1991-07       Impact factor: 4.638

5.  Genetic linkage analysis of a novel syndrome comprising North Carolina-like macular dystrophy and progressive sensorineural hearing loss.

Authors:  P J Francis; S Johnson; B Edmunds; R E Kelsell; E Sheridan; C Garrett; G E Holder; D M Hunt; A T Moore
Journal:  Br J Ophthalmol       Date:  2003-07       Impact factor: 4.638

6.  Phenotype of a British North Carolina macular dystrophy family linked to chromosome 6q.

Authors:  M B Reichel; R E Kelsell; J Fan; C Y Gregory; K Evans; A T Moore; D M Hunt; F W Fitzke; A C Bird
Journal:  Br J Ophthalmol       Date:  1998-10       Impact factor: 4.638

7.  North Carolina Macular Dystrophy Is Caused by Dysregulation of the Retinal Transcription Factor PRDM13.

Authors:  Kent W Small; Adam P DeLuca; S Scott Whitmore; Thomas Rosenberg; Rosemary Silva-Garcia; Nitin Udar; Bernard Puech; Charles A Garcia; Thomas A Rice; Gerald A Fishman; Elise Héon; James C Folk; Luan M Streb; Christine M Haas; Luke A Wiley; Todd E Scheetz; John H Fingert; Robert F Mullins; Budd A Tucker; Edwin M Stone
Journal:  Ophthalmology       Date:  2015-10-24       Impact factor: 12.079

8.  A novel tandem duplication of PRDM13 in a Chinese family with North Carolina macular dystrophy.

Authors:  Shijing Wu; Zhisheng Yuan; Zixi Sun; Tian Zhu; Xing Wei; Xuan Zou; Ruifang Sui
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-08-24       Impact factor: 3.117

9.  Clinical and genetic characterization of a Danish family with North Carolina macular dystrophy.

Authors:  Thomas Rosenberg; Ben Roos; Thorkild Johnsen; Niels Bech; Todd E Scheetz; Michael Larsen; Edwin M Stone; John H Fingert
Journal:  Mol Vis       Date:  2010-12-09       Impact factor: 2.367

10.  Prdm13 forms a feedback loop with Ptf1a and is required for glycinergic amacrine cell genesis in the Xenopus Retina.

Authors:  Nathalie Bessodes; Karine Parain; Odile Bronchain; Eric J Bellefroid; Muriel Perron
Journal:  Neural Dev       Date:  2017-09-01       Impact factor: 3.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.